STOCK TITAN

Neuronetics Inc - STIM STOCK NEWS

Welcome to our dedicated news page for Neuronetics (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neuronetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neuronetics's position in the market.

Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) to present at 35th Annual Piper Sandler Healthcare Conference on November 29, 2023. The management team will present at 2:00 pm Eastern Time via webcast, with a live audio webcast available on the investor relations page of the Company’s website at ir.neuronetics.com. A replay will be archived on the website for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) announces significant updates to the NeuroStar software and TrakStar Patient Data Management System, aimed at advancing practice efficiency and patient outcomes. The updates include a new user interface and platform for NeuroStar, while TrakStar's upgrade enables proactive notifications for patient care and practice management, along with improved outcomes reporting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) announced policy updates from Magellan, BlueCross BlueShield (BCBS) of Kansas City, and Dean Health Plan, increasing access for patients to the Company’s NeuroStar® Advanced Therapy. The changes reduce the number of prior antidepressant medication failures from four to two before coverage for transcranial magnetic stimulation (TMS) therapy for major depressive disorder (MDD). Magellan's update goes into effect on November 18, 2023. The company's CEO, Keith J. Sullivan, expressed optimism about the increased access to mental health coverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.3%
Tags
none
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) reported a third-quarter 2023 revenue of $17.9 million, an 8% increase over the same period in 2022. The company also achieved a record U.S. treatment session revenue of $13.1 million and shipped 43 NeuroStar systems. Neuronetics launched the 'Better Me Guarantee' Provider pilot program and accessed $22.5 million from its existing debt facility. The company also achieved a milestone of over 162,500 global patients treated with 5.9 million treatment sessions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
earnings
-
Rhea-AI Summary
Neuronetics, Inc. has granted inducement awards of Restricted Stock Units (RSUs) to four new non-executive employees. The RSUs represent a total of 18,000 shares of the company's common stock and were approved by Neuronetics' Compensation Committee. The grants vest in three equal installments over three years, subject to continued service. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
-
Rhea-AI Summary
Neuronetics, Inc. plans to release its third quarter 2023 financial and operating results on November 7th, 2023. The conference call to review the results will be held at 8:30 a.m. Eastern Time on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences earnings
Rhea-AI Summary
Neuronetics, Inc. has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners, LLC, strengthening its balance sheet and supporting its strategy execution. The company aims to achieve cash flow break-even in Q4-2024 and on a full-year basis in 2025. This additional capital eliminates the need to access the equity markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
none
-
Rhea-AI Summary
Neuronetics launches NeuroStar Voices Portal to raise awareness for mental health and suicide prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Summary
Neuronetics' NeuroStar Advanced Therapy campaign wins Gold at 2023 dotCOMM Awards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
Neuronetics Inc

Nasdaq:STIM

STIM Rankings

STIM Stock Data

142.83M
22.83M
6.88%
60.59%
0.51%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Malvern

About STIM

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.